Swiss drugmaker Roche upped the company’s bet on personalized cancer treatment and is ready to sell a blood test around the world that can identify common gene mutations from solid tumors from a patient’s blood.
Industry insiders say Johnson & Johnson is no longer interested in Pfizer’s $20 billion consumer healthcare business